文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

遗传性弥漫性胃癌:2022年最新进展

Hereditary Diffuse Gastric Cancer: A 2022 Update.

作者信息

Kole Christo, Charalampakis Nikolaos, Sakellariou Stratigoula, Papaxoinis George, Apostolou Konstantinos G, Machairas Nikolaos, Papanikolaou Ioannis S, Schizas Dimitrios

机构信息

First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 115 27 Athens, Greece.

Department of Medical Oncology, Metaxa Cancer Hospital, 185 37 Athens, Greece.

出版信息

J Pers Med. 2022 Dec 8;12(12):2032. doi: 10.3390/jpm12122032.


DOI:10.3390/jpm12122032
PMID:36556253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9783673/
Abstract

Gastric cancer is ranked fifth among the most commonly diagnosed cancers, and is the fourth leading cause of cancer-related deaths worldwide. The majority of gastric cancers are sporadic, while only a small percentage, less than 1%, are hereditary. Hereditary diffuse gastric cancer (HDGC) is a rare malignancy, characterized by early-onset, highly-penetrant autosomal dominant inheritance mainly of the germline alterations in the E-cadherin gene () and β-catenin (). In the present study, we provide an overview on the molecular basis of HDGC and outline the essential elements of genetic counseling and surveillance. We further provide a practical summary of current guidelines on clinical management and treatment of individuals at risk and patients with early disease.

摘要

胃癌是最常见的诊断癌症中排名第五的癌症,并且是全球癌症相关死亡的第四大主要原因。大多数胃癌是散发性的,而只有不到1%的小部分是遗传性的。遗传性弥漫性胃癌(HDGC)是一种罕见的恶性肿瘤,其特征是早发、具有高外显率的常染色体显性遗传,主要是E-钙黏蛋白基因()和β-连环蛋白()的种系改变。在本研究中,我们概述了HDGC的分子基础,并概述了遗传咨询和监测的基本要素。我们还进一步提供了关于有风险个体和早期疾病患者的临床管理和治疗的当前指南的实用总结。

相似文献

[1]
Hereditary Diffuse Gastric Cancer: A 2022 Update.

J Pers Med. 2022-12-8

[2]
Hereditary diffuse gastric cancer (HDGC). An overview.

Clin Res Hepatol Gastroenterol. 2022-4

[3]
Frequency of and Germline Variants in Families with Diffuse and Mixed Gastric Cancer.

Cancers (Basel). 2023-8-29

[4]
Hereditary diffuse gastric cancer: What the clinician should know.

World J Gastrointest Oncol. 2015-9-15

[5]
Cancer predisposition and germline CTNNA1 variants.

Eur J Med Genet. 2021-10

[6]
CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management.

Cancer Manag Res. 2019-12-13

[7]
Genetic predisposition to gastric cancer.

Semin Oncol. 2016-10

[8]
Gastric cancer: new genetic developments.

J Surg Oncol. 2005-6-1

[9]
Germline mutations in hereditary diffuse gastric cancer.

Chin J Cancer Res. 2018-2

[10]
Hereditary diffuse gastric cancer - pathophysiology and clinical management.

Best Pract Res Clin Gastroenterol. 2014-12

引用本文的文献

[1]
Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present.

Curr Oncol. 2025-2-6

[2]
Hereditary Gastrointestinal Tumor Syndromes: When Risk Comes with Your Genes.

Curr Issues Mol Biol. 2024-6-26

[3]
The relationship between periodontal disease and gastric cancer: A bidirectional Mendelian randomization study.

Medicine (Baltimore). 2024-6-14

本文引用的文献

[1]
CD24: A Novel Target for Cancer Immunotherapy.

J Pers Med. 2022-7-28

[2]
Unexpected Mutations Identified on Multigene Panels Pose Clinical Management Challenges.

JCO Precis Oncol. 2017-11

[3]
Disruption of Wnt/β-catenin Pathway Elevates the Sensitivity of Gastric Cancer Cells to PD-1 Antibody.

Curr Mol Pharmacol. 2022

[4]
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Lancet. 2021-7-3

[5]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[6]
Investigation on the Role of PALB2 Gene in CDH1-Negative Patients With Hereditary Diffuse Gastric Cancer.

Clin Transl Gastroenterol. 2020-12

[7]
α-E-Catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer.

Cancer Manag Res. 2020-12-14

[8]
Hereditary Diffuse Gastric Cancer: Approaches to Screening, Surveillance, and Treatment.

Annu Rev Med. 2021-1-27

[9]
Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell.

Ther Adv Med Oncol. 2020-10-31

[10]
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update.

Cancers (Basel). 2020-10-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索